Anti-Obesity Prescription Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Anti-Obesity Prescription Drugs Market by drug class (orlistat, phentermine and topiramate, bupropion and naltrexone, lorcaserin, liraglutide), distribution channel (retail pharmacy, hospital pharmacy and online pharmacy), age group (pediatric and adult)  market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Anti-Obesity Prescription Drugs Market it includes the five years Industry analysis and the 6 years annual forecast from 2018 to 2024. Some of the prominent participants in the Global Anti-Obesity Prescription Drugs Market are F Hoffmann La Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A/S, Arena Pharmaceuticals, Inc, GlaxoSmithKline, VIVUS, Inc, BoehringerIngelheim, Alizyme and Others. According to the report the Global Anti-Obesity Prescription Drugs Market is projected to grow at a CAGR of 4.97% in terms of value over the period of 2018-2024.

Unhealthy Food which is Rich in Cholesterol has increased which Leads to a Rise in Demand for Anti-Obesity Prescription Drugs

The pharmacological agents that helps to reduce or control weight. Anti-obesity drugs help in reducing body mass either by reducing the hunger or increasing the consumption of calories. The ingesting of unhealthy food which is rich in cholesterol has increased which leads to a rise in demand for anti-obesity prescription drugs. Rising level of chronic stress also contributes towards obesity. Rising consumption of alcoholic beverages and unhealthy food which is rich in cholesterol that leads to obesity is driving the growth of the market.

Obesity Management is expected to Impact Growth of the Global Anti-Obesity Prescription Drugs Market Positively

Growing occurrence of depression has led to growing consumption of the psychotropic drugs; the side effect of this drug is increasing which result to obesity. Moreover, increasing incidences of diabetes have surged up the consumption of medications. These medications have appetite stimulating features, due to which the patients incline to eat more. Eating disorders due to antidepressants and diabetic drugs increase the diet which has sustained to contribute towards obesity. Growing demand for obesity management is expected to impact growth of the global anti-obesity prescription drugs market positively.

Segment Covered

The report on global anti-obesity prescription drugs market covers segments such as, drug class, distribution channel and age group. On the basis of drug class the global anti-obesity prescription drugs market is categorized into orlistat, phentermine and topiramate, bupropion and naltrexone, lorcaserin and liraglutide. On the basis of distribution channel the global anti-obesity prescription drugs market is categorized into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of age group the global anti-obesity prescription drugs market is categorized into pediatric and adult.

U.S. Drives the Growth in the North America Region as it is the Largest Market in the Region

The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section the key trends and market size for each geography is provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China.Countries such as the U.S., the U.K., and France among others have reported substantial rise in the obesity population. Moreover, growing work stress in emerging markets of Asia-pacific is likely to cause rise in obesity cases in the years to come over the next six years. According to the study North America followed by Europe accounted for the largest market share in the word anti-obesity prescription drugs market in 2016 and this trend is projected to continue over the forecast period, with increasing awareness among the people in the U.S. and Canada.

Companies Profiled:

The report provides profiles of the companies in the global anti-obesity prescription drugs market such as, F Hoffmann La Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A/S, Arena Pharmaceuticals, Inc, GlaxoSmithKline, VIVUS, Inc, BoehringerIngelheim, Alizyme and Others. Recently approved Saxenda by Novo Nordisk is growing at a fast growth rate due to rising interest among obese people.Novo Nordisk, an innovator of drugs in the obesity market, introduces Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, This Dual therapy can be used for both obesity and type 2 diabetes is the latest trend in the market.

Table of Contents:

1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

3. Global Anti-obesity Prescription Drugs Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter's Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.5. Competitive Landscape in the Global Anti-obesity Prescription Drugs Market

4. Global Anti-obesity Prescription Drugs Market by Drug Class

4.1. Orlistat

4.2. Phentermine and Topiramate

4.3. Bupropion and Naltrexone

4.4. Lorcaserin

4.5. Liraglutide

5. Global Anti-obesity Prescription Drugs Market by Distribution Channel

5.1. Retail Pharmacy

5.2. Hospital Pharmacy

5.3. Online Pharmacy

6. Global Anti-obesity Prescription Drugs Market by Age Group

6.1. Pediatric

6.2. Adult 

7. Global Anti-obesity Prescription Drugs Market by Region 2018-2024

7.1. North America

7.1.1. North America Anti-obesity Prescription Drugs Market by Drug Class

7.1.2. North America Anti-obesity Prescription Drugs Market by Distribution Channel

7.1.3. North America Anti-obesity Prescription Drugs Market by Age Group

7.1.4. North America Anti-obesity Prescription Drugs Market by Country

7.2. Europe

7.2.1. Europe Anti-obesity Prescription Drugs Market by Drug Class

7.2.2. Europe Anti-obesity Prescription Drugs Market by Distribution Channel

7.2.3. Europe Anti-obesity Prescription Drugs Market by Age Group

7.2.4. Europe Anti-obesity Prescription Drugs Market by Country

7.3. Asia-Pacific

7.3.1. Asia-Pacific Anti-obesity Prescription Drugs Market by Drug Class

7.3.2. Asia-Pacific Anti-obesity Prescription Drugs Market by Distribution Channel

7.3.3. Asia-Pacific Anti-obesity Prescription Drugs Market by Age Group

7.3.4. Asia-Pacific Anti-obesity Prescription Drugs Market by Country

7.4. RoW

7.4.1. RoW Anti-obesity Prescription Drugs Market by Drug Class

7.4.2. RoW Anti-obesity Prescription Drugs Market by Distribution Channel

7.4.3. RoW Anti-obesity Prescription Drugs Market by Age Group

7.4.4. RoW Anti-obesity Prescription Drugs Market by Sub-region

8. Company Covered

8.1. F Hoffmann La Roche Ltd

8.2. Orexigen Therapeutics, Inc

8.3. Novo Nordisk A/s

8.4. Arena Pharmaceuticals, Inc

8.5. Glaxosmithkline

8.6. Vivus, Inc

8.7. BoehringerIngelheim

8.8. Alizyme

8.9. Others

Click the Below Full Report Link: https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_anti-obesity_prescription_drugs_market